Shane A Bobart1,2, Heedeok Han3, Shahrzad Tehranian1, An S De Vriese4,5, Juan Carlos Leon Roman6, Sanjeev Sethi7, Ladan Zand1, Cristina Andrades Gomez8, Callen D Giesen7, Maria Jose Soler9, Andrew S Bomback3, Fernando C Fervenza1. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 2. Department of Nephrology and Hypertension, Cleveland Clinic Florida, Weston, Florida. 3. Division of Nephrology, Columbia University Medical Center, New York, New York. 4. Division of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Brugge, Belgium. 5. Department of Internal Medicine, Ghent University, Ghent, Belgium. 6. Nephrology Department, University Hospital Vall D'Hebron, Barcelona, Spain. 7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 8. Department of Nephrology, Universitario Virgen del Rocio, Sevilla, Andalucía, Spain. 9. Nephrology Department, University Hospital Vall D'Hebron, Barcelona, Spain mjsoler01@gmail.com Fervenza.fernando@mayo.edu.
Abstract
BACKGROUND AND OBJECTIVES: Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%-80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions (e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D'Hebron (Barcelona), and the Columbia University Medical Center (New York) were retrospectively reviewed. Biopsy findings and presence or absence of a potential associated condition were assessed. RESULTS: From a total of 276 patients with positive anti-phospholipase A2 receptor serology, previously reported patients (n=33), kidney transplant recipients (n=9), pediatric patients (n=2), and patients without kidney biopsy (n=69) were excluded. Among the 163 remaining patients, associated conditions were identified in 47 patients, and 15 patients had diabetes mellitus. All 101 patients of the final cohort had a primary diagnosis of membranous nephropathy on kidney biopsy. In the 79 patients with eGFR≥60 ml/min per 1.73 m2, none of the biopsy findings altered diagnosis or management. Among the 22 patients with decreased eGFR, additional findings included superimposed acute interstitial nephritis (n=1). CONCLUSIONS: In patients with preserved eGFR and absence of associated conditions or diabetes, a positive anti-phospholipase A2 receptor test by either ELISA >20 RU/ml or a positive immunofluorescence assay confirms the diagnosis of membranous nephropathy, precluding the requirement for a kidney biopsy.
BACKGROUND AND OBJECTIVES: Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%-80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions (e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D'Hebron (Barcelona), and the Columbia University Medical Center (New York) were retrospectively reviewed. Biopsy findings and presence or absence of a potential associated condition were assessed. RESULTS: From a total of 276 patients with positive anti-phospholipase A2 receptor serology, previously reported patients (n=33), kidney transplant recipients (n=9), pediatric patients (n=2), and patients without kidney biopsy (n=69) were excluded. Among the 163 remaining patients, associated conditions were identified in 47 patients, and 15 patients had diabetes mellitus. All 101 patients of the final cohort had a primary diagnosis of membranous nephropathy on kidney biopsy. In the 79 patients with eGFR≥60 ml/min per 1.73 m2, none of the biopsy findings altered diagnosis or management. Among the 22 patients with decreased eGFR, additional findings included superimposed acute interstitial nephritis (n=1). CONCLUSIONS: In patients with preserved eGFR and absence of associated conditions or diabetes, a positive anti-phospholipase A2 receptor test by either ELISA >20 RU/ml or a positive immunofluorescence assay confirms the diagnosis of membranous nephropathy, precluding the requirement for a kidney biopsy.
Authors: Emilio D Poggio; Robyn L McClelland; Kristina N Blank; Spencer Hansen; Shweta Bansal; Andrew S Bomback; Pietro A Canetta; Pascale Khairallah; Krzysztof Kiryluk; Stewart H Lecker; Gearoid M McMahon; Paul M Palevsky; Samir Parikh; Sylvia E Rosas; Katherine Tuttle; Miguel A Vazquez; Anitha Vijayan; Brad H Rovin Journal: Clin J Am Soc Nephrol Date: 2020-10-15 Impact factor: 8.237
Authors: Beatriz Pombas; Eva Rodríguez; Juan Sánchez; Aleksandar Radosevic; Javier Gimeno; Marcos Busto; Clara Barrios; Laia Sans; Julio Pascual; María José Soler Journal: Kidney Blood Press Res Date: 2019-12-10 Impact factor: 2.687
Authors: Shree G Sharma; Andrew S Bomback; Jai Radhakrishnan; Leal C Herlitz; Michael B Stokes; Glen S Markowitz; Vivette D D'Agati Journal: Clin J Am Soc Nephrol Date: 2013-07-25 Impact factor: 8.237
Authors: An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2016-10-24 Impact factor: 10.121
Authors: Fernando C Fervenza; Roshini S Abraham; Stephen B Erickson; Maria Valentina Irazabal; Alfonso Eirin; Ulrich Specks; Patrick H Nachman; Eric J Bergstralh; Nelson Leung; Fernando G Cosio; Marie C Hogan; John J Dillon; LaTonya J Hickson; Xujian Li; Daniel C Cattran Journal: Clin J Am Soc Nephrol Date: 2010-08-12 Impact factor: 8.237
Authors: Jürgen Floege; Sean J Barbour; Daniel C Cattran; Jonathan J Hogan; Patrick H Nachman; Sydney C W Tang; Jack F M Wetzels; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Brad H Rovin Journal: Kidney Int Date: 2019-02 Impact factor: 10.612
Authors: Ragnar Palsson; Samuel A P Short; Zoe A Kibbelaar; Afolarin Amodu; Isaac E Stillman; Helmut G Rennke; Gearoid M McMahon; Sushrut S Waikar Journal: Kidney Int Rep Date: 2020-03-04